Schonfeld Strategic Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMDX
BC
AIC
PVI
DC
Schonfeld Strategic Advisors's IMDX Position: Q3 2023 in Review
Schonfeld Strategic Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 985 shares — an estimated $4.53K sold.
Schonfeld Strategic Advisors first reported a position in IMDX in Q1 2019 and held it in 13 quarters. The position peaked at $8.42M in Q1 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.
- Schonfeld Strategic Advisors reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 985 Insight Molecular Diagnostics shares in Q3 2023, an estimated $4.53K.
- Schonfeld Strategic Advisors first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 13 quarters.
- Schonfeld Strategic Advisors's Insight Molecular Diagnostics position peaked at $8.42M in Q1 2021.
- 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.
Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.